4/21/2022 – Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics

4/20/2022 – Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study

4/19/2022 – Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group

4/6/2022 – Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label

4/4/2022 – Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

4/1/2022 – UPDATE: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

3/31/2022 – Todos Medical Reports Case Study of Patient with Long COVID

3/28/2022 – Billy Blanks Endorses Todos Medical's Line of Tollovid Products

3/17/2022 – Todos Medical to Present at the Proactive One2One Virtual Forum

3/16/2022 – Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma

3/15/2022 – Todos Medical to Present at the Emerging Growth Conference

3/8/2022 – Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs